Evaluation of Pexion® (imepitoin) for treatment of storm anxiety in dogs: A randomised, double-blind, placebo-controlled trial.
Irina PerdewCarrie EmkeBrianna JohnsonVaidehi DixitYukun SongEmily H GriffithPhilip WatsonMargaret E GruenPublished in: The Veterinary record (2021)
Imepitoin was significantly superior to placebo in storm logs and weekly surveys for weeks 2 and 4, and in the end-of-study survey. Mild/moderate adverse events were reported in 26 patients (24 active: two placebo); the most frequent adverse event was ataxia. Owners of dogs in the imepitoin group, compared to placebo, were significantly more likely to report that treatment reduced their dogs fear and anxiety during storms (p < 0.001) and other noise events (p < 0.001). Twice daily administration of imepitoin decreased anxiety scores in dogs with storm anxiety. Future work may evaluate optimal dosage regimens.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase iii
- sleep quality
- end stage renal disease
- study protocol
- cross sectional
- newly diagnosed
- physical activity
- ejection fraction
- randomized controlled trial
- open label
- air pollution
- phase ii
- peritoneal dialysis
- early onset
- current status
- combination therapy
- depressive symptoms
- prognostic factors
- adverse drug